Metraipolis › archive › dc_0bc796dd79af

Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study — Europe PMC PMID:41208873

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41208873
DOI
10.3389/fphar.2025.1621795
License (as archived)
solo-consultazione
Archived
2026-11-09T02:18:07.522Z
SHA-256 of the archived text
14bfc57af9734078cb16c8ee3812fb36d8a6b4701ded2da8ba77c0c82c4b9ac1
Stable URL of this page
https://metraipolis.com/documento/dc_0bc796dd79af

How to cite

Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study — Europe PMC PMID:41208873 — Europe PMC (en), https://europepmc.org/article/MED/41208873 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0bc796dd79af (Metraipolis archive dc_0bc796dd79af, sha256 14bfc57af9734078cb16c8ee3812fb36d8a6b4701ded2da8ba77c0c82c4b9ac1)
BibTeX
@misc{dc0bc796dd79af,
  title = {Rituximab in PR3-ANCA positive patients with moderately to severely active ulcerative colitis: a multicenter real-world pilot study — Europe PMC PMID:41208873},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41208873},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0bc796dd79af; sha256 14bfc57af9734078cb16c8ee3812fb36d8a6b4701ded2da8ba77c0c82c4b9ac1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41208873. Agents can read the archived copy with the MCP tool read_document.